血清尿酸在心血管疾病中的研究进展
Progress in Studying Serum Uric Acid in Cardiovascular Diseases
DOI: 10.12677/ACM.2023.132251, PDF,   
作者: 布阿依夏·阿拉拜地, 梁晓慧*：新疆医科大学第一附属医院高血压科，新疆 乌鲁木齐
关键词: 尿酸；心血管疾病；机制；Uric Acid； Cardiovascular Diseases； Mechanism
摘要: 尿酸是人体嘌呤代谢的终产物。国内外研究表明尿酸不仅是痛风的原因，而且可能在心血管疾病的发生中发挥作用。几项临床研究已报告血清尿酸可作为心血管结局的预测标志物。尽管高尿酸血症与心血管疾病的因果关系仍存在争议，但由于全球高尿酸血症患病率的增加，人们对尿酸的兴趣越来越大。本文就UA与心血管疾病的发病机制及ULT治疗心血管疾病的疗效作一综述。
Abstract: Uric acid is an end product of purine metabolism in humans. Domestic and foreign studies have shown that uric acid is not only the cause of gout, but also may play a role in the development of cardiovascular diseases. Several clinical studies have reported that serum uric acid can serve as a predictive marker of cardiovascular outcome. Although the causal relationship between hyperu-ricemia and cardiovascular disease remains controversial, the interest in uric acid is increasing due to the increased prevalence of hyperuricemia worldwide. This paper summarizes the pathogenesis of UA and the efficacy of ULT in the treatment of cardiovascular diseases.
文章引用：布阿依夏·阿拉拜地, 梁晓慧. 血清尿酸在心血管疾病中的研究进展[J]. 临床医学进展, 2023, 13(2): 1812-1818. https://doi.org/10.12677/ACM.2023.132251

参考文献

[1] 《中国心血管健康与疾病报告2021》要点解读[J]. 中国心血管杂志, 2022, 27(4): 305-318.
[2] Ndrepepa, G., Braun, S., King, L., et al. (2012) Association of Uric Acid with Mortality in Patients with Stable Coronary Artery Dis-ease. Metabolism, 61, 1780-1786. [Google Scholar] [CrossRef] [PubMed]
[3] Wei, F., Sun, N., Cai, C., et al. (2016) Associations between Serum Uric Acid and the Incidence of Hypertension: A Chinese Senior Dynamic Cohort Study. Journal of Translational Medicine, 14, Article No. 110. [Google Scholar] [CrossRef] [PubMed]
[4] Okazaki, H., Shirakabe, A., Kobayashi, N., et al. (2016) The Prognostic Impact of Uric Acid in Patients with Severely Decompensated Acute Heart Failure. Journal of Cardiology, 68, 384-391. [Google Scholar] [CrossRef] [PubMed]
[5] Yu, W. and Cheng, J.-D. (2020) Uric Acid and Cardio-vascular Disease: An Update from Molecular Mechanism to Clinical Perspective. Frontiers in Pharmacology, 11, Article ID: 582680. [Google Scholar] [CrossRef] [PubMed]
[6] Chaudhary, K., Malhotra, K., Sowers, J. and Aroor, A. (2013) Uric Acid-Key Ingredient in the Recipe for Cardiorenal Metabolic Syndrome. Cardiorenal Medicine, 3, 208-220. [Google Scholar] [CrossRef] [PubMed]
[7] Furuhashi, M. (2020) New Insights into Purine Metabolism in Metabolic Diseases: Role of Xanthine Oxidoreductase Activity. American Journal of Physiology-Endocrinology and Metabolism, 319, E827-E834. [Google Scholar] [CrossRef] [PubMed]
[8] 中国高尿酸血症与痛风诊疗指南(2019) [J]. 中华内分泌代谢杂志, 2020(1): 1-13.
[9] Virdis, A., Masi, S., Casiglia, E., Tikhonoff, V., Cicero, A.F.G., Ungar, A., et al. (2020) Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality over 20 Years. Hypertension, 75, 302-308. [Google Scholar] [CrossRef] 
[10] Liu, R., Han, C., Wu, D., et al. (2015) Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. BioMed Research International, 2015, Article ID: 762820. [Google Scholar] [CrossRef] [PubMed]
[11] Klisic, A., Kocic, G., Kavaric, N., Jovanovic, M., Stanisic, V. and Ninic, A. (2018) Xanthine Oxidase and Uric Acid as Independent Predictors of Albuminuria in Patients with Diabetes Mellitus Type 2. Clinical and Experimental Medicine, 18, 283-290. [Google Scholar] [CrossRef] [PubMed]
[12] Kang, D.H., Park, S.K., Lee, I.K., et al. (2005) Uric Acid-Induced C-Reactive Protein Expression: Implication on Cell Prolifera-tion and Nitric Oxide Production of Human Vascular Cells. Journal of the American Society of Nephrology, 16, 3553-3562. [Google Scholar] [CrossRef] 
[13] Masuo, K., Kawaguchi, H., Mikami, H., et al. (2003) Serum Uric Acid and Plasma Norepinephrine Concentrations Predict Subsequent Weight Gain and Blood Pressure Ele-vation. Hypertension, 42, 474-480. [Google Scholar] [CrossRef] 
[14] Bjornstad, P., Laffel, L., Lynch, J., El Ghormli, L., Weinstock, R.S., Tollefsen, S.E., et al. (2019) Elevated Serum Uric Acid Is Associated with Greater Risk for Hyperten-sion and Diabetic Kidney Diseases in Obese Adolescents with Type 2 Diabetes: An Observational Analysis from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. Diabetes Care, 42, 1120-1128. [Google Scholar] [CrossRef] [PubMed]
[15] Verdecchia, P., Schillaci, G., Reboldi, G., Santeusanio, F., Porcellati, C. and Brunetti, P. (2000) Relation between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension. The PIUMA Study. Hypertension, 36, 1072-1078. [Google Scholar] [CrossRef] 
[16] Sanchez-Lozada, L.G., Tapia, E., Soto, V., et al. (2008) Treatment with the Xanthine Oxidase Inhibitor Febuxostat Lowers Uric Acid and Alleviates Systemic and Glomerular Hypertension in Experimental Hyperuricaemia. Nephrology Dialysis Transplantation, 23, 1179-1185. [Google Scholar] [CrossRef] [PubMed]
[17] Feig, D.I., Soletsky, B. and Johnson, R.J. (2008) Effect of Allopurinol on Blood Pressure of Adolescents with Newly Diagnosed Essential Hypertension: A Randomized Trial. JAMA, 300, 924-932. [Google Scholar] [CrossRef] [PubMed]
[18] Soletsky, B. and Feig, D.I. (2012) Uric Acid Reduction Rec-tifies Prehypertension in Obese Adolescents. Hypertension, 60, 1148-1156. [Google Scholar] [CrossRef] 
[19] Higgins, P., Walters, M.R., Murray, H.M., et al. (2014) Allopurinol Reduces Brachial and Central Blood Pressure, and Carotid Intima-Media Thickness Progression after Ischaemic Stroke and Transient Ischaemic Attack: A Randomised Controlled Trial. Heart, 100, 1085-1092. [Google Scholar] [CrossRef] [PubMed]
[20] Fromonot, J., Deharo, P., Bruzzese, L., et al. (2016) Adenosine Plasma Level Correlates with Homocysteine and Uric Acid Concentrations in Patients with Coronary Artery Disease. Canadian Journal of Physiology and Pharmacology, 94, 272-277. [Google Scholar] [CrossRef] [PubMed]
[21] Braga, F., Pasqualetti, S., Ferraro, S. and Panteghini, M. (2016) Hyperuricemia as Risk Factor for Coronary Heart Disease Incidence and Mortality in the General Population: A System-atic Review and Meta-Analysis. Clinical Chemistry and Laboratory Medicine, 54, 7-15. [Google Scholar] [CrossRef] [PubMed]
[22] Ai, X.M., Wei, L., Ma, L.L., Chen, H.Y., Zhang, Z.J., Ji, Z.F., et al. (2015) Serum Uric Acid and Its Relationship with Cardiovascular Risk Profile in Chinese Patients with Early-Onset Coronary Artery Disease. Clinical Rheumatology, 34, 1605-1611. [Google Scholar] [CrossRef] [PubMed]
[23] Wang, R., Song, Y., Yan, Y. and Ding, Z. (2016) Elevated Serum Uric Acid and Risk of Cardiovascular or All-Cause Mortality in People with Suspected or Definite Coronary Artery Disease: A Meta-Analysis. Atherosclerosis, 254, 193-199. [Google Scholar] [CrossRef] [PubMed]
[24] Kimura, Y., Yanagida, T., Onda, A., Tsukui, D., Ho-soyamada, M. and Kono, H. (2020) Soluble Uric Acid Promotes Atherosclerosis via AMPK (AMPActivated Protein Kinase)-Mediated Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 40, 570-582. [Google Scholar] [CrossRef] 
[25] Pavlusova, M., Jarkovsky, J., Benesova, K., Vitovec, J., Linhart, A., Widimsky, P., et al. (2019) Hyperuricemia Treatment in Acute Heart Failure Patients Does Not Improve Their Long-Term Prognosis: A Propensity Score Matched Analysis from the AHEAD Registry. Clinical Cardiology, 42, 720-727. [Google Scholar] [CrossRef] [PubMed]
[26] Huang, H., Huang, B., Li, Y., Huang, Y., Li, J., Yao, H., et al. (2014) Uric Acid and Risk of Heart Failure: A Systematic Review and Meta-Analysis. European Journal of Heart Fail-ure, 16, 15-24. [Google Scholar] [CrossRef] [PubMed]
[27] Li, Z., Shen, Y., Chen, Y., Zhang, G., Cheng, J. and Wang, W. (2018) High Uric Acid Inhibits Cardiomyocyte Viability Through the ERK/P38 Pathway via Oxidative Stress. Cellular Physiology and Biochemistry, 45, 1156-1164. [Google Scholar] [CrossRef] [PubMed]
[28] Lin, W.D., Deng, H., Guo, P., Liu, F.Z., Chen, R.Y., Fang, X.H., et al. (2019) High Prevalence of Hyperuricaemia and Its Impact on Non-Valvular Atrial Fibrillation: The Cross-Sectional Guangzhou (China) Heart Study. BMJ Open, 9, e028007. [Google Scholar] [CrossRef] [PubMed]
[29] Celik, M., Yalcinkaya, E., Yuksel, U.C., Gokoglan, Y., Bugan, B., Kabul, H.K., et al. (2015) Increased Serum Uric Acid Lev-els Are Correlated with Decreased Left Atrial Appendage Peak Flow Velocity in Patients with Atrial Fibrillation. Medical Principles and Practice, 24, 263-268. [Google Scholar] [CrossRef] [PubMed]
[30] Black-Maier, E. and Daubert, J.P. (2019) Editorial Commentary: Prevention and Treatment of Atrial Fibrillation: Is Hyperuricemia the Next Target? Trends in Cardiovascular Medicine, 29, 48-49. [Google Scholar] [CrossRef] [PubMed]
[31] Maharani, N., Ting, Y.K., Cheng, J., Hasegawa, A., Kurata, Y., Li, P., et al. (2015) Molecular Mechanisms Underlying Urate-Induced Enhancement of Kv1.5 Channel Expression in HL-1 Atrial Myocytes. Circulation Journal, 79, 2659- 2668. [Google Scholar] [CrossRef] 
[32] White, W.B., Saag, K.G., Becker, M.A., Borer, J.S., Gorelick, P.B., Whelton, A., et al. (2018) Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. The New England Journal of Medicine, 378, 1200-1210. [Google Scholar] [CrossRef] 
[33] Wilcox, C.S., Shen, W., Boulton, D.W., Leslie, B.R. and Griffen, S.C. (2018) Interaction between the Sodium-Glu- cose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diu-retic Bumetanide in Normal Human Subjects. Journal of the American Heart Association, 7, e007046. [Google Scholar] [CrossRef] 
[34] Xin, Y., Guo, Y., Li, Y., Ma, Y., Li, L. and Jiang, H. (2019) Ef-fects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus: A Systematic Re-view with an Indirect Comparison Meta-Analysis. Saudi Journal of Biological Sciences, 26, 421-426. [Google Scholar] [CrossRef] [PubMed]
[35] Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., et al. (2019) Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 380, 347-357. [Google Scholar] [CrossRef] 

为你推荐